Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CCNK | O75909 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.30 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953317 | 1.00 | CCNT1 (0.30) | CCNT1CCNKCDK7CDK9CCNH | |
| SCHEMBL13906778 | 0.95 | CCNT1 (0.31) | CCNT1CCNKCDK7CDK9CCNH | |
| SCHEMBL3959198 | 0.95 | CCNT1 (0.31) | CCNT1CCNKCDK7CDK9CCNH | |
| SCHEMBL3957319 | 0.91 | LMNA (0.30) | — | |
| SCHEMBL13905109 | 0.91 | LMNA (0.30) | — | |
| SCHEMBL3948809 | 0.91 | LMNA (0.32) | — | |
| SCHEMBL4020116 | 0.91 | LMNA (0.32) | — | |
| SCHEMBL13906749 | 0.91 | LMNA (0.32) | — | |
| SCHEMBL13906783 | 0.89 | ADORA2A (0.32) | CCNT1CCNKCDK7CDK9CCNH | |
| SCHEMBL3951374 | 0.89 | ADORA2A (0.32) | CCNT1CCNKCDK7CDK9CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PNP, SLC29A1, SLC28A1 | CCNT1 671/4885CCNK 1179/4885CDK7 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.